ON4 Stock Overview Produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Ono Pharmaceutical Co., Ltd. Competitors Price History & Performance
Summary of share price highs, lows and changes for Ono Pharmaceutical Historical stock prices Current Share Price JP¥10.10 52 Week High JP¥15.80 52 Week Low JP¥9.50 Beta 0.17 1 Month Change -11.40% 3 Month Change n/a 1 Year Change -34.84% 3 Year Change -52.80% 5 Year Change -51.44% Change since IPO -50.16%
Recent News & Updates
First half dividend of JP¥40.00 announced Jan 22
Ono Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Feb 03, 2025 Nov 21
Upcoming dividend of JP¥40.00 per share Sep 20
Ono Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Oct 31, 2024 Aug 24
Ono Pharmaceutical Co., Ltd. Announces U.S. Food and Drug Administration Accepts for Priority Review Deciphera’s New Drug Application for Vimseltinib for the Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT) Aug 16
First quarter 2025 earnings released: EPS: JP¥52.79 (vs JP¥65.16 in 1Q 2024) Aug 05 See more updates
First half dividend of JP¥40.00 announced Jan 22
Ono Pharmaceutical Co., Ltd. to Report Q3, 2025 Results on Feb 03, 2025 Nov 21
Upcoming dividend of JP¥40.00 per share Sep 20
Ono Pharmaceutical Co., Ltd. to Report Q2, 2025 Results on Oct 31, 2024 Aug 24
Ono Pharmaceutical Co., Ltd. Announces U.S. Food and Drug Administration Accepts for Priority Review Deciphera’s New Drug Application for Vimseltinib for the Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT) Aug 16
First quarter 2025 earnings released: EPS: JP¥52.79 (vs JP¥65.16 in 1Q 2024) Aug 05
Dividend of JP¥40.00 announced Aug 05
European Medicines Agency Accepts Deciphera's Marketing Authorization Application for Vimseltinib for Treatment of Patients with Tenosynovial Giant Cell Tumor (TGCT) Jul 19
Final dividend of JP¥40.00 announced Jul 12
Full year 2024 earnings released: EPS: JP¥267 (vs JP¥231 in FY 2023) Jun 27
Less than half of directors are independent Jun 18
Ono Pharmaceutical Co., Ltd. to Report Q1, 2025 Results on Jul 31, 2024 Jun 17 Ono Pharmaceutical Co., Ltd. (TSE:4528) completed the acquisition of Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) from BlackRock, Inc. (NYSE:BLK), Deerfield Capital, L.P., Redmile Group, LLC Brightstar Associates, LLC and others. Jun 13
Less than half of directors are independent May 17
Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 20, 2024 May 11 Ono Pharmaceutical Co., Ltd. (TSE:4528) entered into a definitive merger agreement to acquire Deciphera Pharmaceuticals, Inc. (NasdaqGS:DCPH) for $2.2 billion. Apr 30
Ono Pharmaceutical Co., Ltd. to Report Fiscal Year 2024 Results on May 09, 2024 Mar 28
Upcoming dividend of JP¥40.00 per share Mar 21
ONO Pharmaceuticals, Co., Ltd. Announces Enrollment is Complete for the First Arm of the PROSPECT Study of Tirabrutinib in U.S. Patients with Relapsed or Refractory PCNSL Mar 21
Third quarter 2024 earnings released: EPS: JP¥75.73 (vs JP¥68.23 in 3Q 2023) Feb 02
First half dividend of JP¥40.00 announced Jan 16
Ono Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Jan 31, 2024 Dec 19
Less than half of directors are independent Dec 11
Less than half of directors are independent Nov 07
Upcoming dividend of JP¥40.00 per share at 2.8% yield Sep 21
Ono Pharmaceutical Co., Ltd. to Report Q2, 2024 Results on Nov 01, 2023 Aug 31
First quarter 2024 earnings released: EPS: JP¥65.16 (vs JP¥60.37 in 1Q 2023) Aug 02
Ono Pharmaceutical Co., Ltd. (TSE:4528) announces an Equity Buyback for 19,000,000 shares, representing 3.89% for ¥50,000 million. Jul 25
Ono Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023 Jun 07
Less than half of directors are independent May 19
Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 22, 2023 May 13
Less than half of directors are independent Mar 29
Less than half of directors are independent Feb 17
Third quarter 2023 earnings released: EPS: JP¥68.23 (vs JP¥36.83 in 3Q 2022) Feb 02
Ono Pharmaceutical Co., Ltd. (TSE:4528) acquired Research assets related to multiple research-stage oncology programs from KSQ Therapeutics, Inc. Jan 27
Less than half of directors are independent Dec 28
Ono Pharmaceutical Co., Ltd. to Report Q3, 2023 Results on Jan 31, 2023 Nov 27
Less than half of directors are independent Nov 18
Second quarter 2023 earnings released: EPS: JP¥67.30 (vs JP¥44.51 in 2Q 2022) Nov 02
Less than half of directors are independent Oct 07
Ono Pharmaceutical Co., Ltd. to Report Q2, 2023 Results on Oct 31, 2022 Aug 31
First quarter 2023 earnings released: EPS: JP¥60.37 (vs JP¥48.23 in 1Q 2022) Aug 02
Investor sentiment improved over the past week Jul 11
Less than half of directors are independent Jun 20
Ono Pharmaceutical Co., Ltd. to Report Q1, 2023 Results on Aug 01, 2022 May 29
Full year 2022 earnings released: EPS: JP¥162 (vs JP¥151 in FY 2021) May 13
Ono Pharmaceutical Co., Ltd., Annual General Meeting, Jun 23, 2022 May 13
Less than half of directors are independent Apr 27
Ono Pharmaceutical Co., Ltd. to Report Fiscal Year 2022 Results on May 11, 2022 Apr 08
Less than half of directors are independent Apr 06
Upcoming dividend of JP¥28.00 per share Mar 23
Less than half of directors are independent Feb 24
Less than half of directors are independent Feb 08
Third quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat Feb 03
Ono Pharmaceutical Co., Ltd. (TSE:4528) announces an Equity Buyback for 11,000,000 shares, representing 2.2% for ¥30,000 million. Nov 27
Less than half of directors are independent Nov 18
Second quarter 2022 earnings released: EPS JP¥44.51 (vs JP¥36.77 in 2Q 2021) Nov 03
Upcoming dividend of JP¥28.00 per share Sep 22
Exelixis, Inc. Announces Partner Takeda Pharmaceutical Company Limited and Ono Receive Approval in Japan for CABOMETYX in Combination with Opdivo for the Treatment of Unresectable or Metastatic Renal Cell Carcinoma Aug 26
First quarter 2022 earnings released: EPS JP¥48.23 (vs JP¥43.07 in 1Q 2021) Aug 04
Full year 2021 earnings released Jun 24
Full year 2021 earnings released: EPS JP¥151 (vs JP¥118 in FY 2020) May 14
Upcoming dividend of JP¥22.50 per share Mar 23
Ono Pharmaceutical Co., Ltd. to Report Fiscal Year 2021 Results on May 11, 2021 Mar 04
New 90-day low: €23.00 Feb 24
Third quarter 2021 earnings released: EPS JP¥53.37 (vs JP¥38.09 in 3Q 2020) Feb 04
Revenue beats expectations Feb 04
ONO Receives a Manufacturing and Marketing Approval of Adlumiz (Anamorelin), a Ghrelin Receptor Agonist for the Treatment of Cancer Cachexia in Japan Jan 22
New 90-day low: €23.20 Jan 05
Ono Pharmaceutical Co., Ltd. to Report Q3, 2021 Results on Feb 01, 2021 Nov 29
Revenue beats expectations Nov 11
Second quarter 2021 earnings released: EPS JP¥36.77 Nov 11
First half earnings released Nov 01
Semi-annual earnings released: Revenue beats expectations Nov 01
New 90-day high: €27.20 Sep 18
Ono Pharmaceutical Co., Ltd. to Report Q2, 2021 Results on Oct 29, 2020 Sep 03
New 90-day high - €26.40 Aug 19
First quarter earnings released Aug 08 Shareholder Returns ON4 DE Pharmaceuticals DE Market 7D -11.4% 1.9% 2.3% 1Y -34.8% -12.6% 11.9%
See full shareholder returns
Return vs Market: ON4 underperformed the German Market which returned 11.9% over the past year.
Price Volatility Is ON4's price volatile compared to industry and market? ON4 volatility ON4 Average Weekly Movement n/a Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.8% 10% most volatile stocks in DE Market 10.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: ON4's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine ON4's volatility change over the past year.
About the Company Ono Pharmaceutical Co., Ltd., together with its subsidiaries, produces, purchases, and sells pharmaceuticals and diagnostic reagents worldwide. It offers Opdivo Intravenous Infusion and Kyprolis Intravenous Injection for malignant tumors; Emend capsules/Proemend intravenous injections for chemotherapy-induced nausea and vomiting; Demser capsules for the symptoms in patients with pheochromocytoma; and Mektovi, Velexbru, and Braftovi capsules for malignant tumors, as well as ADLUMIZ tablets for cancer cachexia. The company also provides Glactiv tablets for type 2 diabetes; Forxiga tablets for diabetes; Onoact Intravenous Infusion for tachyarrhythmia; Opalmon tablets to treat peripheral circulatory disorder; Coralan for chronic heart failure; Orencia injections for rheumatoid arthritis; Rivastach patches for Alzheimer’s disease; Ongentys tablets for Parkinson’s disease; Parsabiv, an intravenous infusion for dialysis patients; Staybla tablets for overactive bladder; Onon capsules and Dry Syrups for bronchial asthma and allergic rhinitis; and JOYCLU intra-articular injection for the improvement of joint function, as well as Recalbon tablets for osteoporosis.
Show more Ono Pharmaceutical Co., Ltd. Fundamentals Summary How do Ono Pharmaceutical's earnings and revenue compare to its market cap? ON4 fundamental statistics Market cap €4.62b Earnings (TTM ) €585.12m Revenue (TTM ) €2.98b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) ON4 income statement (TTM ) Revenue JP¥484.30b Cost of Revenue JP¥119.24b Gross Profit JP¥365.06b Other Expenses JP¥269.93b Earnings JP¥95.13b
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 03, 2025
Earnings per share (EPS) 202.52 Gross Margin 75.38% Net Profit Margin 19.64% Debt/Equity Ratio 19.0%
How did ON4 perform over the long term?
See historical performance and comparison Dividends
5.0% Current Dividend Yield When do you need to buy ON4 by to receive an upcoming dividend? Ono Pharmaceutical dividend dates Ex Dividend Date Mar 28 2025 Dividend Pay Date Jun 23 2025 Days until Ex dividend 63 days Days until Dividend pay date 150 days
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/23 22:21 End of Day Share Price 2025/01/23 00:00 Earnings 2024/09/30 Annual Earnings 2024/03/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Ono Pharmaceutical Co., Ltd. is covered by 24 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Atsushi Seki Barclays Koichi Mamegano BofA Global Research Aaron Ho CFRA Equity Research
Show 21 more analysts 
